Prognostic significance of p53 gene mutations in laryngeal cancer

被引:34
作者
Chomchai, JS
Du, W
Sarkar, FH
Li, YW
Jacobs, JR
Ensley, JF
Sakr, W
Yoo, GH
机构
[1] Wayne State Univ, Dept Otolaryngol, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA
[3] Wayne State Univ, Dept Med Oncol, Detroit, MI 48201 USA
关键词
D O I
10.1097/00005537-199903000-00021
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective/Hypothesis: We examined whether p53 gene mutations were predictive of clinical behavior in laryngeal cancer. Study Design: Retrospective study of 45 patients with laryngeal cancer from 1985 to 1997, Methods: DNA was extracted from tumor tissue and subject to polymerase chain reaction single-strand conformational polymorphism (PCR-SSCP) as well as DNA sequencing. The clinical outcome was correlated to the presence or absence of a p53 mutation. Results: The p53 gene was analyzed by direct DNA sequencing and was found to be mutated in 33% (15/45) of patients. The presence of a p53 mutation was associated with a significant improvement in overall survival (80% vs. 49%, P <.03) and a trend toward improved disease-free survival (87% vs, 60%, P =.08). When other prognostic factors were adjusted, multivariate analysis revealed a trend toward improvement in overall survival as well as disease-free survival. Conclusion: Depending on the location of a p53 mutation, the suppressive functions or clinical outcome may or may not be affected. Fifty-three percent of mutations were detected in nonconserved regions as opposed to 17% as reported in colon cancer. In colon cancer, mutations in conserved regions of the p53 gene predicted a poorer survival, whereas nonconserved gene mutations were not predictive. In our group of patients, p53 mutations predicted a better prognosis, which may be due to a large proportion of mutations that lie within nonconserved areas. The predictive power of p53 gene mutations may depend on functional loss and inactivation of highly conserved areas and must be tested in a prospective trial.
引用
收藏
页码:455 / 459
页数:5
相关论文
共 22 条
  • [1] Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma
    Bourhis, J
    Lubin, R
    Roche, B
    Koscielny, S
    Bosq, J
    Dubois, I
    Talbot, M
    Marandas, P
    Schwaab, G
    Wibault, P
    Luboinski, B
    Eschwege, F
    Soussi, T
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) : 1228 - 1233
  • [2] BOYLE JO, 1993, CANCER RES, V53, P4477
  • [3] Bradford CR, 1997, ARCH OTOLARYNGOL, V123, P605
  • [4] CAAMANO J, 1993, AM J PATHOL, V142, P1131
  • [5] Chiarugi V, 1996, TUMORI, V82, P205
  • [6] Coggi G, 1997, CANCER, V79, P425, DOI 10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO
  • [7] 2-H
  • [8] GOH HS, 1995, CANCER RES, V55, P5217
  • [9] Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
    Harris, CC
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20): : 1442 - 1455
  • [10] The molecular epidemiology of P53 gene mutations in human breast cancer
    Hartmann, A
    Blaszyk, H
    Kovach, JS
    Sommer, SS
    [J]. TRENDS IN GENETICS, 1997, 13 (01) : 27 - 33